InterCure Ltd.

Tel Aviv Stock Exchange INCR.TA

InterCure Ltd. EBITDA Margin for the year ending December 31, 2023: -6.72%

InterCure Ltd. EBITDA Margin is -6.72% for the year ending December 31, 2023, a -140.51% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

InterCure Ltd. EBITDA Margin for the year ending December 31, 2022 was 16.59%, a -2.65% change year over year.
InterCure Ltd. EBITDA Margin for the year ending December 31, 2021 was 17.05%, a 132.11% change year over year.
InterCure Ltd. EBITDA Margin for the year ending December 31, 2020 was -53.09%, a 77.65% change year over year.
InterCure Ltd. EBITDA Margin for the year ending December 31, 2019 was -237.55%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tel Aviv Stock Exchange: INCR.TA

InterCure Ltd.

CEO	Mr. Alexander Rabinovich
IPO Date	Sept. 9, 2007
Location	Israel
Headquarters	85 Medinat ha-Yehudim Street
Employees	270
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years